Replies to post #72478 on Biotech Values

[genisi]

Prasugrel panel

I don’t see why analysts are talking about
an unduly narrow label inasmuch as the restrictions cited in the
briefing doc are the same ones LLY itself has proposed.

Agree - nothing new and sounds positive.